Skip to Content
  • Sodium Benzoate Nonsense

    I don’t spend a lot of time on the blog swatting down idiotic ideas about chemicals. It’s a full time job, and (see next post) I already have a full… Read More
  • Glioblastoma Is Bad News, Period

    Everyone keeping up with the news will have heard about Sen. McCain’s diagnosis of glioblastoma multiforme (GBM). This is not good news at all; GBM is a v… Read More
  • Model This?

    Via Ash Jogalekar on Twitter, I came across this new paper from researchers at AstraZeneca (and collaborators in Sweden, the UK, and Denmark) on the synthesis a… Read More
  • Following Up

    Here’s a question that I’m not sure if there’s a general answer to: if you’re putting together a drug discovery portfolio, what percenta… Read More
  • Changes in NIH Grant Policy?

    There are some pretty big funding changes being proposed at the NIH that many people may not be aware of. A concerned NIH grantee has sent along some links and… Read More
  • Aggregator Aggravation, In a New Way

    Experienced drug discovery folks, particularly those that work early on in the process, will tell you that aggregation is one of the most common sources of fals… Read More
  • More Spring-Loaded Reagents

    I wrote just about this time last year about a new “strain-release” bond forming reaction system from the Baran group at Scripps. Now they’ve… Read More
  • The Flightosome

    I got this diagram from Arjun Raj‘s Twitter feed, and I think I enjoy it a bit more every time I see it. Some of that is because it’s a big part of… Read More
  • Curcumin Will Waste Your Time

    I really enjoyed reading this article in J. Med. Chem. on curcumin. (Update: here’s the take over at Practical Fragments). That’s a well-known natur… Read More
  • Watson and Pfizer

    I have wondered several times around here about how (and if) IBM’s Watson platform is going to be able to help out with drug discovery, and it looks like… Read More
Page 1 of 1012345...10...Last »